EMT(SH:601208)2022-04-29 16:00Financial Performance - The company's operating revenue for Q1 2022 was RMB 904,402,611.18, representing a 21.15% increase compared to RMB 746,533,732.06 in the same period last year[7]. - Net profit attributable to shareholders was RMB 101,756,880.47, up 19.77% from RMB 84,956,803.84 in the previous year[7]. - Total operating revenue for Q1 2022 was ¥904,402,611.18, an increase of 21.1% compared to ¥746,533,732.06 in Q1 2021[32]. - Net profit for Q1 2022 reached ¥102,333,430.67, representing a 20.0% increase from ¥85,268,586.14 in Q1 2021[35]. - The total comprehensive income attributable to shareholders for Q1 2022 was ¥101,756,880.47, compared to ¥84,956,803.84 in Q1 2021, indicating a growth of 19.7%[37]. Cash Flow - The net cash flow from operating activities was negative at RMB -107,963,187.87, a significant decline of 594.05% compared to RMB -15,555,557.57 in the same period last year[7]. - In Q1 2022, the company reported cash inflows from operating activities of ¥474,003,988.09, an increase from ¥343,570,778.24 in Q1 2021, representing a growth of approximately 38.0%[39]. - The net cash outflow from operating activities was ¥107,963,187.87, compared to a net outflow of ¥15,555,557.57 in the same period last year, indicating a significant decline in operational cash flow[39]. - The company recorded cash inflows from investment activities totaling ¥337,824,594.41, while cash outflows amounted to ¥514,907,938.38, resulting in a net cash outflow of ¥177,083,343.97 for the investment activities[41]. - Total cash inflows from financing activities reached ¥896,602,741.42, a substantial increase from ¥380,000,000.00 in Q1 2021, reflecting a growth of approximately 136.0%[41]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 6,797,973,140.31, an increase of 11.33% from RMB 6,106,061,712.49 at the end of the previous year[9]. - Current assets totaled approximately CNY 2.89 billion, up from CNY 2.43 billion, indicating a growth of around 18.6% year-over-year[26]. - Total liabilities increased to ¥2,969,657,332.01 in Q1 2022, compared to ¥2,403,246,930.14 in Q1 2021, reflecting a growth of 23.6%[29]. - The total liabilities increased to CNY 2,207,377,256.00 from CNY 1,878,579,839.44, which is an increase of approximately 17.48%[50]. Equity - The company's equity attributable to shareholders increased by 2.91% to RMB 3,692,853,399.92 from RMB 3,588,528,924.17 at the end of the previous year[9]. - Total equity attributable to shareholders rose to ¥3,692,853,399.92 in Q1 2022, up from ¥3,588,528,924.17 in Q1 2021, marking an increase of 2.9%[29]. - The company’s total equity increased to CNY 2,801,468,669.64 from CNY 2,784,642,198.28, reflecting a growth of approximately 0.60%[50]. Expenses - The company experienced a 34.72% increase in selling expenses, attributed to higher personnel costs[12]. - Research and development expenses for Q1 2022 were ¥27,529,994.41, a decrease from ¥33,013,234.44 in Q1 2021[32]. - Research and development expenses for Q1 2022 were CNY 15,215,884.75, slightly down from CNY 16,129,936.72 in Q1 2021, indicating a decrease of about 5.66%[52]. Other Information - The company has not disclosed any new product developments or market expansion strategies during this reporting period[20]. - There are no known related party transactions among the top shareholders, except for the identified consistent action relationship among certain shareholders[20]. - The company reported a credit impairment loss of ¥4,767,070.38 in Q1 2022, an improvement from ¥7,981,849.39 in Q1 2021[35]. - The company has implemented new accounting standards starting from 2022, affecting the financial statements[61].